TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07409246: A Phase 1, First-in-Human, Open Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ABBV-438 in Adult Subjects With Relapsed or Refractory Multiple Myeloma

Sponsor: AbbVie · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 127 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$7,037,184

Rescue Site Savings

+$4,649,568

Unlock Full NCT07409246 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07409246 Rescue Dossier →